The molecular diagnostics market is shifting from large laboratories to distributed and point-of-care solutions. Significant growth is expected between 2024 and 2030, driven by portable PCR, multiplex testing and cloud/AI integration. Ulisse Biomed, with its Hyris System™ platform (bCUBE™, bAPP™, ambient-stable reagents), is positioning itself as an end-to-end player capable of scaling this revolution.

The convergence of PCR and artificial intelligence in the Ulisse Biomed ecosystem enables standardised interpretation of Ct curves, real-time quality control and centralised governance of distributed networks. The result is a faster, more reliable and scalable diagnostic cycle.

Personalised medicine replaces the “one-size-fits-all” model with tailored treatments based on genetic and molecular profiles. The article shows how multiplex diagnostics—decentralised, modular and integrable—enable faster and more sustainable treatment pathways, with Ulisse Biomed as the infrastructure enabler.

Modular qPCR testing quantifies Akkermansia, Faecalibacterium, Lactobacillus and Bifidobacterium within hours, enabling customised pathways and Diagnostics as a Service models.